InvestorsHub Logo
Followers 0
Posts 3727
Boards Moderated 0
Alias Born 10/23/2017

Re: None

Sunday, 07/18/2021 11:50:42 AM

Sunday, July 18, 2021 11:50:42 AM

Post# of 718028
We are coming up against the one year mark from official trial completion. Without request for extension for a valid reason, NWBO HAS to release the data. I believe they have it ready to go and are waiting for peer review to be completed. They will wait as long as possible to have TLD and Journal as close together as possible. But, they are up against the 1yr mark of trial end.

Official Trial Completion Date: (per August 19th, 2020 PR) Probably happened a few days prior to PR.
"...today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer as described in the Company’s last report on July 24, 2020 has now been completed by the specialty analytics firms. With this data now in hand, final quality control checking and confirmation are under way to enable Data Lock."

We are one month away (worst case), IMO, from topline. Yes, they could ask for extension due to covid, etc., but that would have to be disclosed. Peer-review has likely been ongoing and no Journal can prevent NWBO from adhering to FDA or SEC rules for disclosure of data or material events. We also have a 10Q due by August 15th. I am hoping there is no vague language hinting at extension of time for data release.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News